Novartis to challenge Colombia price cut on Glivec

23 December 2016

Following the Colombian Ministry of Health’s recent decision to lower the price of its cancer drug Glivec/Gleevec (imatinib), Swiss pharma giant Novartis (NOVN: VX) has advised The Pharma Letter that it proposes to take action.

In an emailed statement, Novartis said it has made the difficult decision to file an Annulment Action in Colombia challenging the Ministry of Health’s decision to enforce a Declaration of Public Interest (DPI) on its life-saving cancer medicine Glivec.

Novartis added that it is aware and sympathetic to the financial challenges faced by Colombia’s healthcare system and is committed to seeking solutions to benefit patients, innovation and the Colombian economy. For many months, the company faithfully negotiated with the Colombian government to identify acceptable solutions, but a resolution was not reached, stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK